Search | Clinical Trials Finder

Conditions: Mild Cognitive Impairment, Cognitive Impairment, Alzheimer Disease
Interventions: Insulin (Humulin® R U-100), Empagliflozin 10 MG, Aptar Pharma CPS Intranasal Delivery Device, Placebo (Insulin Diluent), Placebo (Capsules); Drug · Device
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 55 Years to 85 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Diabetes Mellitus, Type 2
Interventions: Empagliflozin, Dipeptidyl Peptidate-4 inhibitors; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 62,197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Chronic Kidney Disease
Interventions: Vicadrostat, Empagliflozin, Placebo matching vicadrostat; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 492 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 37
States / cities: Huntsville, Alabama • Anaheim, California • San Dimas, California + 33 more

Conditions: Diabetes Mellitus, Type 2
Interventions: SGLT2, Metformin; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 20,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type2 Diabetes, Insulin Sensitivity
Interventions: Empagliflozin 25 MG; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Prediabetes
Interventions: Empagliflozin 10mg daily, Lifestyle education; Drug · Other
Lead sponsor: Charles George VA Medical Center; Federal
Eligibility: 35 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Asheville, North Carolina

Conditions: Diabetic Kidney Disease, Diabetes Mellitus Type 2
Interventions: Empagliflozin, Placebo; Drug · Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 64 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Chronic Kidney Disease, Type 2 Diabetes
Interventions: Finerenone, Semaglutide, Lotensin, Capoten, Enalapril, Monopril, Lisinopril, Univasc, Aceon, Accupril, Altace, Mavik, Edarbi, Atacand, Avapro, Cozaar, Benicar, Micardis, Diovan, Invokana, Farxiga, Jardiance, Ertugliflozin, Brenzavvy, Sotagliflozin; Drug
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 84 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Temple, Texas

Conditions: Heart Failure
Interventions: Empagliflozin, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 41
States / cities: Mobile, Alabama • Saraland, Alabama • Huntington Beach, California + 37 more

Conditions: Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
Interventions: Vicadrostat, Empagliflozin, Placebo matching Vicadrostat; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 11,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 210
States / cities: Anniston, Alabama • Fairhope, Alabama • Guntersville, Alabama + 173 more

Conditions: Non-diabetic Chronic Kidney Disease
Interventions: Empagliflozin, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Myocardial Infarction
Interventions: Empagliflozin, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 6,522 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 85
States / cities: Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 75 more

Conditions: Major Depressive Disorder
Interventions: Empagliflozin; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Obesity, Vascular Health
Interventions: Empagliflozin, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 30 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Type 1 Diabetes Mellitus, Glucokinase-Maturity Onset Diabetes of the Young (GCK-MODY), MODY2 Diabetes, Healthy Volunteer
Interventions: Study Visit 1, Placebo, Study Visit 2, Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor; Procedure · Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Diabetes Mellitus, Type 2
Interventions: DPP4, GLP-1 receptor agonist, Basal Insulin, SLGT2, SU; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 30 Years and older
Enrollment: 550,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: Wilmington, Delaware • Lexington, Kentucky • Boston, Massachusetts + 2 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo identical to BI 10773 high dose, Placebo identical to BI 10773 low dose, BI 10773; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,504 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 25
States / cities: Birmingham, Alabama • Tempe, Arizona • Huntington Park, California + 21 more

Conditions: Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), Albuminuria
Interventions: Empagliflozin (oral); Drug
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetes
Interventions: Empagliflozin, DPP-4 inhibitor; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 120 Years
Enrollment: 103,752 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus, Type 2
Interventions: BI 10773, Metformin, Sitagliptin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 12
States / cities: Mission Viejo, California • Spring Valley, California • Walnut Creek, California + 9 more

Conditions: Liver Diseases, Hypertension, Portal
Interventions: Avenciguat, Empagliflozin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 4
States / cities: Pasadena, California • Rialto, California • Miami Lakes, Florida + 1 more

Conditions: End Stage Renal Disease on Dialysis
Interventions: Empagliflozin 25 mg vs Placebo, Empagliflozin 10 MG; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Hepatic Glucose Metabolism
Interventions: Empagliflozin 25 MG, Control; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Covid19
Interventions: theraputic heparin, prophylactic heparin, P2Y12, Crizanlizumab Injection, SGLT2 inhibitor; Drug
Lead sponsor: Matthew Neal MD; Other
Eligibility: 18 Years and older
Enrollment: 3,591 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 81
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 65 more

Search by objective public record fields.

SNIFF - Combo INI+EMPA Trial

Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

Metformin And Cardiovascular Effectiveness vs SGLT2 (MACES)

Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 Diabetes

Evaluation of Empagliflozin vs Standard Care in Veterans With Prediabetes

Empaglifozin in Early Diabetic Kidney Disease

Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)

This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

Vascular Effects of SGLT2i in Non-diabetic CKD

EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)

Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity

Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes

BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes

Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes

Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin

Replication of the EMPAREG Diabetes Trial in Healthcare Claims

Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension

A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease

Empagliflozin and Hepatic Glucose Metabolism

Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE